Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

Key Takeaway: Assertio has completed its merger with Zydus Lifesciences, which includes a fundamental change regarding its outstanding 6.50% convertible senior notes due in 2027. This merger may impact the company's financial structure and future operations. Further details on the implications of this merger were not provided.